Duc Nguyen, DO
Interventional Cardiology · Cape Girardeau, MONPI 1437193026
Payments from drug & device makers
Across 427 payments — averaging $49.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$5K
- Medtronic$4K
- Boston Scientific$3K
- Edwards Lifesciences$3K
- Abbott$1K
- Biotronik Inc.$752
- plus $4K from 30 others
What the payments were for
- Travel & lodging$6,22929%
- Food & beverage$14,77670%
- Education$2001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 51 | $5,274 |
| Medtronic(2 entities) | 50 | $3,554 |
| Boston Scientific | 98 | $3,457 |
| Edwards Lifesciences | 33 | $2,640 |
| Abbott | 34 | $1,243 |
| Biotronik Inc. | 11 | $752 |
| Shockwave Medical, Inc | 13 | $650 |
| Amgen | 26 | $444 |
| Johnson & Johnson | 29 | $394 |
| AstraZeneca | 5 | $376 |
| E.r. Squibb & Sons, L.L.C. | 6 | $277 |
| Cathworks, Inc. | 4 | $260 |
| Siemens Medical Solutions USA, Inc. | 5 | $242 |
| Daiichi Sankyo Inc. | 3 | $201 |
| Cvrx, Inc. | 2 | $178 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $154 |
| Esperion Therapeutics, Inc. | 4 | $134 |
| Boehringer Ingelheim | 4 | $133 |
| Bridgebio Pharma, Inc. | 1 | $117 |
| ZOLL Circulation Inc | 3 | $117 |
| Biosense Webster, Inc. | 3 | $105 |
| Novartis | 7 | $102 |
| Pfizer | 6 | $73 |
| Regeneron Healthcare Solutions, Inc. | 4 | $58 |
| Stryker | 2 | $55 |
| Lundbeck LLC | 2 | $30 |
| Convatec Inc. | 1 | $26 |
| Akcea Therapeutics, Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Atricure, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$3,254
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,711
- ONYX FRONTIER$672
- LINQ II$515
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$388
- AVVIGO Guidance System$264
- FFRangio$256
- FARXIGA$248
- SYMPLICITY G3$156
- Barostim Neo System$154
- Assurity Pacemaker$152
- WATCHMAN Access System$148
- ENSITE$147
- INJECTAFER$142
- CoreValve Evolut$137
- HeartMate 3 Left Ventricular Assist Device$125
- CAMZYOS$125
- Attruby$117
- SYNERGY$112
- ENSITE PRECISION$108
How this compares
$21,205 in reported general payments places this provider in the 60th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 936 | $669,738 |
| EntrestoSacubitril/Valsartan | 595 | $496,197 |
| Repatha SureclickEvolocumab | 365 | $217,972 |
| XareltoRivaroxaban | 266 | $190,189 |
| JardianceEmpagliflozin | 180 | $132,133 |
| Praluent PenAlirocumab | 71 | $38,857 |
| FarxigaDapagliflozin Propanediol | 49 | $33,153 |
| BrilintaTicagrelor | 33 | $17,485 |
| Metoprolol Succinate | 874 | $8,092 |
| Repatha SyringeEvolocumab | 14 | $7,693 |
| CorlanorIvabradine Hcl | 12 | $7,198 |
| Ranolazine ErRanolazine | 59 | $6,183 |
| Atorvastatin Calcium | 985 | $5,115 |
| Nebivolol Hcl | 104 | $4,713 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 206 | $4,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $73 | $669,738936 claims |
| NovartisEntresto | $102 | $496,197595 claims |
| Johnson & JohnsonXarelto | $394 | $190,189266 claims |
| Boehringer IngelheimJardiance | $133 | $132,133180 claims |
| AstraZenecaFarxiga, Brilinta | $376 | $50,63882 claims |
| AmgenCorlanor | $444 | $7,19812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Cape Girardeau
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$995K
- Jasvindar SinghSaint Louis$993K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.